June 2026 - Corcept Therapeutics

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

June 22, 2026

DeFronzo et al. • 2026 • Heart in Diabetes

Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)

June 18, 2026

Lorusso et al. • 2026 • ESMO Gyn

Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)

June 18, 2026

Shahin et al. • 2026 • ESMO Gyn

Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies

June 15, 2026

DeFronzo et al. • 2026 • ENDO

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

June 15, 2026

Eilerman et al. • 2026 • ENDO

High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study

June 8, 2026

Umpierrez et al. • 2026 • ADA

Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs

June 6, 2026

Sloan et al. • 2026 • ADA